Literature DB >> 30296479

Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America.

Nandita Khera1, Betty K Hamilton2, Joseph A Pidala3, William A Wood4, Vicky Wu5, Jenna Voutsinas5, Lynn Onstad5, Amin M Alousi6, Raewyn Broady7, George L Chen8, Mukta Arora9, Corey Cutler10, Mary E Flowers5, Alex Ganetsky11, Madan Jagasia12, Philip L McCarthy8, Stefanie Sarantopoulos13, Gregory A Abel10, Navneet S Majhail2, Stephanie J Lee5.   

Abstract

Understanding the socioeconomic impact of chronic graft-versus-host disease (GVHD) on affected patients is essential to help improve their overall well-being. Using data from the Chronic GVHD Consortium, we describe the insurance, employment, and financial challenges faced by these patients and the factors associated with the ability to work/attend school and associated financial burdens. A 15-item cross-sectional questionnaire designed to measure financial concerns, income, employment, and insurance was completed by 190 patients (response rate, 68%; 10 centers) enrolled on a multicenter Chronic GVHD Consortium Response Measures Validation Study. Multivariable logistic regression models examined the factors associated with financial burden and ability to work/attend school. The median age of respondents was 56years, and 87% of the patients were white. A higher proportion of nonrespondents had lower income before hematopoietic cell transplantation and less than a college degree. All but 1 patient had insurance, 34% had faced delayed/denied insurance coverage for chronic GVHD treatments, and 66% reported a financial burden. Patients with a financial burden had greater depression/anxiety and difficulty sleeping. Nonwhite race, lower mental functioning, and lower activity score were associated with a greater likelihood of financial burden. Younger age, early risk disease, and higher mental functioning were associated with a greater likelihood of being able to work/attend school. In this multicenter cohort of patients with chronic GVHD, significant negative effects on finances were observed even with health insurance coverage. Future research should investigate potential interventions to provide optimal and affordable care to at-risk patients and prevent long-term adverse financial outcomes in this vulnerable group.
Copyright © 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Financial hardship; chronic GVHD; hematopoietic cell transplantation

Mesh:

Year:  2018        PMID: 30296479      PMCID: PMC6445749          DOI: 10.1016/j.bbmt.2018.09.040

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  9 in total

Review 1.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

2.  Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.

Authors:  Julia Ruark; Erin Mullane; Nancy Cleary; Ana Cordeiro; Evandro D Bezerra; Vicky Wu; Jenna Voutsinas; Bronwen E Shaw; Kathryn E Flynn; Stephanie J Lee; Cameron J Turtle; David G Maloney; Jesse R Fann; Merav Bar
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-09       Impact factor: 5.742

3.  Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.

Authors:  Erica D Warlick; Celalettin Ustun; Astrid Andreescu; Anthony F Bonagura; Andrew Brunner; Abhinav B Chandra; James M Foran; Mark B Juckett; Tamila L Kindwall-Keller; Virginia M Klimek; Daniel F Pease; David P Steensma; Bryce M Waldman; Mary M Horowitz; Linda J Burns; Nandita Khera
Journal:  Cancer       Date:  2021-08-10       Impact factor: 6.860

4.  Psychosocial and financial issues after hematopoietic cell transplantation.

Authors:  David Buchbinder; Nandita Khera
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 5.  Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation.

Authors:  Neel S Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2022-10-04       Impact factor: 4.213

6.  Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada.

Authors:  Sonya Cressman; Donna E Hogge; Mark D Minden; Stephen Couban; Aly Karsan; Raewyn Broady; Emily McPherson; Khalif Halani; Jing Yi Weng; Stuart J Peacock
Journal:  EJHaem       Date:  2020-07-10

7.  Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease.

Authors:  Frida Schain; Nurgul Batyrbekova; Johan Liwing; Simona Baculea; Thomas Webb; Mats Remberger; Jonas Mattsson
Journal:  Eur J Health Econ       Date:  2020-12-04

Review 8.  Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.

Authors:  Daniel Wolff; Giancarlo Fatobene; Vanderson Rocha; Nicolaus Kröger; Mary E Flowers
Journal:  Bone Marrow Transplant       Date:  2021-07-03       Impact factor: 5.483

9.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report.

Authors:  Carrie L Kitko; Joseph Pidala; Hélène M Schoemans; Anita Lawitschka; Mary E Flowers; Edward W Cowen; Eric Tkaczyk; Nosha Farhadfar; Sandeep Jain; Philipp Steven; Zhonghui K Luo; Yoko Ogawa; Michael Stern; Greg A Yanik; Geoffrey D E Cuvelier; Guang-Shing Cheng; Shernan G Holtan; Kirk R Schultz; Paul J Martin; Stephanie J Lee; Steven Z Pavletic; Daniel Wolff; Sophie Paczesny; Bruce R Blazar; Stephanie Sarantopoulos; Gerard Socie; Hildegard Greinix; Corey Cutler
Journal:  Transplant Cell Ther       Date:  2021-04-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.